Green JB, Everett BM, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, et al
Can Anabolic Steroids Cause Gynecomastia
& Romero-Gomez, M
The SURPASS trial indicated a higher incidence of injection site responses than placebo, which were mild to moderate ( Gastrointestinal events were the most common treatment-emergent ADEs in several clinical trials, and most were mild to moderate in intensity ( We also identified unexpected signals, such as impaired gastric emptying (n = 181, ROR 16.60, PRR 16.57, IC 3.89, EBGM 14.81), abnormal gastrointestinal sounds (n = 37, ROR 5.28, PRR 5.27, IC 2.35, EBGM 5.11), and projectile vomiting (n = 22, ROR 8.09, PRR 8.09, IC 2.94, EBGM 7.67)
The STEP 1 trial for semaglutide 2.4mg (Wegovy dose) enrolled a much larger population of 1,961 participants over 68 weeks